The latest findings presented today at the 2014 San Antonio Breast Cancer Symposium (SABCS) show that investigational first-line treatment with fulvestrant...
Eli Lilly announced that results from the Phase III MONARCH 2 study showed that LY 2835219 (abemaciclib) in combination with...
New data from the Phase III FALCON trial demonstrates superior median progression-free survival (PFS) for Faslodex (fulvestrant 500mg), from AstraZeneca,...
Pfizer Inc. announced study results demonstrating Ibrance (palbociclib) in combination with fulvestrant was superior to treatment with a standard of...
Novartis has announced positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer....
The National Institute of Health and Care Excellence (NICE) released draft guidance recommending against use of Faslodex (fulvestrant) from AstraZeneca...